Related Experiment Video
Updated: Mar 18, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
Published on: November 24, 2021
Generic formulations: availability and applicability for exposure assessment
Rosemary T Zaleski1, Andreas Ahrens2, Richard A Becker3
1Lumina Consulting L.L.C., Hillsborough, NJ, USA. rzaleski10@gmail.com.
Background:
Generic formulations (GFs), representations of the composition of consumer and industrial products based upon function rather than specific substances, can be useful tools for exposure and risk assessors. They provide a way to share the information needed for screening assessments of product safety without disclosing specific product formulations. GFs provide a structure for organizing the product/process type and associated qualitative and quantitative chemical ingredient information.
Objective:
This perspective seeks to explain and highlight how GFs can be useful in exposure and risk evaluation, provides examples of GF information sources, and offers suggestions for further development of GFs. The primary emphasis here is on available information for industrial products, as this space is historically data-poor with respect to publicly available GF information.
Methods:
Publicly accessible GF references were located and mapped to the Organization for Economic Co-operation and Development (OECD) harmonized use categories. Authors' personal knowledge of sources of GFs played a key role because a great deal of GF-related information is embedded within spreadsheets or documents posted on the European Chemical Agency (ECHA) website or websites of commercial enterprises, and these sources may not be readily identified using typical internet or literature search strategies.
Results:
Industrial GF information was found for 13 of 20 OECD use categories, but only for 20 of 91 OECD product-subcategory combinations. Limitations in findability and disparity in availability across sources support the value of developing common, consistent practices and platforms across stakeholder communities for sharing GFs and other exposure-relevant information.
Significance:
This paper highlights available data, makes the case for systematic development and public availability of GF data, and explains the benefits of having this information available for various user sectors.
More Related Videos
10:10Assessment of the Acute Inhalation Toxicity of Airborne Particles by Exposing Cultivated Human Lung Cells at the Air-Liquid Interface
Published on: February 23, 2020
08:25Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioequivalence: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Modified-Release Drug Delivery Systems: Bioavailability
Dosage Regimen: Individualization